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Therapeutic options to inhibit the growth and spread of neuroendocrine (NE) gastrointestinal tumours are still limited. Since gefitinib
(4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline), an inhibitor of epidermal growth factor receptor-
sensitive tyrosine kinase (EGFR-TK), had been shown to suppress potently the growth of various non-NE tumour entities, we studied
the antineoplastic potency of gefitinib in NE gastrointestinal tumour cells. In human insulinoma (CM) cells, in human pancreatic
carcinoid (BON) cells and in NE tumour cells of the gut (STC-1), gefitinib induced a time- and dose-dependent growth inhibition by
almost 100%. The antiproliferative potency of gefitinib correlated with the proliferation rate of the tumour cells. So the IC50 value of
gefitinib was 4.770.6mM in the fast-growing CM cells, still 16.870.4mM in the moderate-growing BON cells, and up to 31.572.5mM
in the slow-growing STC-1 cells. Similarly, the induction of apoptosis and cell-cycle arrest by gefitinib differed according to growth
characteristics: fast-growing CM cells displayed a strong G0/G1 arrest in response to gefitinib, while no significant cell-cycle alterations
were seen in the slow-growing STC-1. Vice versa, the proapoptotic effects of gefitinib, as determined by caspase-3 activation and
DNA fragmentation, were most pronounced in the slow-growing STC-1 cells. Using cDNA microarrays, we found extensive changes
in the expression of genes involved in the regulation of apoptosis and cell cycle after incubation with gefitinib. Among them, an
upregulation of the growth arrest and DNA damage-inducible gene GADD153 was observed. Phosphorylation of ERK1/2, which
inhibits GADD153 expression, was reduced in a time-dependent manner. However, no gefitinib-induced activation of the
GADD153-inducing p38 mitogen-activated protein kinase was detected. Our data demonstrate that the inhibition of EGFR-TK by
gefitinib induces growth inhibition, apoptosis and cell-cycle arrest in NE gastrointestinal tumour cells. Thus, EGFR-TK inhibition
appears to be a promising novel approach for the treatment of NE tumour disease.
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Gastrointestinal neuroendocrine (NE) tumours represent a rare
and rather heterogeneous tumour entity. Almost half of the
metastatic NE gastrointestinal tumours release excessive amounts
of biogenic amines and/or neuropeptides, thereby causing a
characteristic hypersecretion syndrome. The often bizarre clinical
symptoms are generally well controlled by somatostatin analogues
or interferon-a (Faiss et al, 1996; O ¨berg, 2001). Therapeutic
options to inhibit growth and further spread of metastatic NE
tumours are yet very limited. Conventional chemotherapy is
indicated in patients with anaplastic and fast-growing NE tumours,
but provides no survival benefit for patients with slow disease
progression. In the light of the particular biology of NE tumour
disease, innovative treatment strategies should be developed that
are both effective and well tolerated.
Recently, evidence has been accumulated indicating that the
epidermal growth factor receptor (EGFR) is a promising target for
novel cancer therapy. A great variety of tumours show abnormal,
enhanced and/or constitutive expression of EGFR. Moreover,
EGFR (over-) expression has been correlated with disease stage,
reduced survival, development of tumour metastases and tumour
differentiation in various cancers (Baselga, 2002; Di Lorenzo et al,
2002; Peghini et al, 2002). Several reports indicate that EGFR are
expressed frequently in NE tumours in general (Wang et al, 1997;
Ezzat, 2001), and in gastrointestinal NE tumours in particular
(Nilsson et al, 1993, 1995; O ¨berg, 1994; Shimizu et al, 2000; Peghini
et al, 2002). In addition, EGFR contributes to the growth
characteristics of NE tumours (Nilsson et al, 1995; Wulbrand
et al, 1998; Peghini et al, 2002). Hence, EGFR is an attractive target
for innovative treatment strategies in gastrointestinal NE tumour
disease.
The EGFR is part of a subfamily of four closely related receptors:
EGFR (ErbB-1), HER-2/neu (ErbB-2), HER-3 (ErbB-3) and HER-4
(ErbB-4). Upon ligand binding EGFR becomes activated by
dimerisation. The receptor activation leads to the subsequent
activation of EGFR tyrosine kinase (TK) enzymatic activity, which
plays a central role in receptor-mediated signal transduction, cell
mitogenesis and cell transformation (Baselga, 2002). Inhibiting
EGFR and their specific TK activity is regarded as a very promising
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(Arteaga, 2002).
Gefitinib (4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-mor-
pholinopropoxy)quinazoline (ZD1839)), a specific EGFR-TK
inhibitor, is currently in clinical testing for various tumour entities
(Baselga et al, 2002; Herbst, 2002). Gefitinib is a low molecular
weight (MW: 447), synthetic anilinoquinazoline. The orally
available and reversibly acting drug is highly specific for EGFR-
TK, exhibiting almost no activity against other TKs and several
serine/threonine kinases (Woodburn et al, 1998; Ciardiello and
Tortora, 2001). Antineoplastic properties of gefitinib have been
demonstrated in a wide range of human cancers, including
prostate, breast, ovarian, colon, epidermoid and lung cancer cells
(Ciardiello et al, 2000; Cullinane et al, 2000; Sirotnak et al, 2000;
Chan et al, 2001; Di Lorenzo et al, 2002; Sewell et al, 2002).
EGFR-TK inhibition has not yet been evaluated in the
antineoplastic treatment of NE tumours. Hence, in the present
study, we examined the antineoplastic potency of the selective
EGFR-TK inhibitor gefitinib in a set of NE gastrointestinal tumour
cell lines with different growth characteristics. We focused on
gefitinib-induced growth inhibition, its induction of apoptosis and
regulation of the cell-cycle in NE gastrointestinal tumour cells.
MATERIAL AND METHODS
Cell lines
Human pancreatic carcinoid BON cells (Ahnert-Hilger et al, 1996;
Lemmer et al, 2002) were maintained in a 1:1 mixture of DMEM,
and F12K medium containing 10% FCS (Biochrom, Berlin,
Germany) and 1% L-glutamine. The human insulinoma cell line
CM (Baroni et al, 1999), kindly provided by Professor P Pozzilli
(University La Sapienza of Rome, Italy), was cultured in RPMI
1640 supplemented with 5% FCS (Biochrom) and 1% L-glutamine.
The murine intestinal NE tumour cell line STC-1 (Ho ¨pfner et al,
2002), which was a gift from Dr D Hanahan (University of
California, San Francisco, CA, USA), was maintained in DMEM
supplemented with 15% horse serum (Biochrom), 2.5% FCS
(Biochrom) and 1% L-glutamine. All cell lines were kept at 371C
in a humidified atmosphere (5% CO2).
Drugs
Gefitinib was a kind gift from AstraZeneca, Great Britain.
Nonradiolabelled meta-iodobenzylguanidine (MIBG) was kindly
provided by Amersham Buchler (Braunschweig, Germany). Stock
solutions were prepared in DMSO and stored at  201C. The drugs
were diluted in fresh media before each experiment. In all
experiments, the final DMSO concentration was o0.5%. To
evaluate the effects of gefitinib and/or meta-iodobenzylguanidine,
cells were incubated with either control medium or a medium
containing rising concentrations of the respective drug or drug
combination. Media were changed daily to ensure constant drug
concentrations in the incubation medium.
Reverse transcriptase–polymerase chain reaction
(RT–PCR)
The total RNA was extracted from cultured cell lines with
RNAClean, following the recommendation of the manufacturer
(Hybaid, London, UK). Reverse transcription and PCR reactions
were carried out as described elsewhere in detail (Glassmeier et al,
1998). To eliminate any possible contamination with genomic
DNA, RNAs were treated with 1U DNAse I (Gibco, Karlsruhe,
Germany) per mg RNA for 15min at room temperature. The
possible contamination with genomic DNA was excluded by
control experiments omitting the reverse transcriptase. Purified
RNA was reverse transcribed into cDNA using oligo-dT-primers
and the SuperScript Preamplification-Kit (Gibco). PCR reactions
were carried out in a total volume of 50ml containing 400nM of
each primer, 200mM of each dNTP (Pharmacia, Uppsala, Sweden),
50mM KCl, 1.5mM MgCl2,1 0 m M tris(hydroxymethyl)-amino-
methane (Tris) and 1U Taq-Polymerase (Pharmacia). PCR was
performed in a Peltier thermocycler (PTC-200, MJ Research,
Watertown, MA, USA) with primers and conditions as indicated in
Table 1.
cDNA array
For determination of gefitinib-induced differential gene expres-
sion, human CM insulinoma cells were treated with gefitinib
(10mM) for 48h. Untreated cells served as controls. Isolation of the
total RNA of treated and untreated cells was performed as
described above. Polyadenylated (polyA
þ) mRNAs were enriched
using magnetic Dynabeads, according to the instructions of the
supplier (Dynal, Oslo, Norway). The quality of total and polyA
þ
RNA was controlled by agarose gel electrophoresis. Labelled first-
strand cDNA probes were prepared from the polyA
þ RNAs of
both gefitinib-treated and control samples. Each sample was
hybridised to an individual membrane of identically spotted 205
apoptosis- and cell-cycle-related genes (Human Apoptosis Array;
Clontech, Palo Alto, CA, USA). A complete list of the cDNAs and
controls as well as their accession numbers is available on the web
(http://atlasinfo.clontech.com/genelists/huApop.xls). After wash-
ing, according to the manufacturer’s instructions, the membranes
were exposed to an X-ray film for quantification. Alteration in the
expression of a respective gene is given as fold increase/or decrease
compared with the signal of the untreated control (Ho ¨pfner et al,
Table 1 Primer sequences and PCR conditions for the detection of mRNA expression of the indicated genes in NE gastrointestinal tumour cells
Genes Primers (50–30)
Position in the
mRNA
Product size
(bp)
Denaturating
temperature
and time (s)
Annealing
temperature
and time (s)
Extension
temperature
and time (s)
Number of
cycles
EGFR-1 F: TCCTCCCAGTGCCTGAATAC 3442–3462 240 941C (40) 631C (60) 721C (60) 30
R: TAATTTGGTGGCTGCCTTTC 3682–3663
EGFRvIII
a F: GGCTCTGGAGGAAAAGAAAG 255–274 226 941C (40) 631C (60) 721C (60) 30
R: TGATGGAGGTGCAGTTTTTG 1282–1263
IGRR-b1 F: GAAGTGGAACCCTCCCTCTC 1932–1951 241 941C (40) 631C (60) 721C (60) 30
R: GTTCTCGGCTTCAGTTTTGG 2172–2153
b-actin F: ATCATGTTTGAGACCTTCAACAC 437–459 822 941C (40) 631C (60) 721C (60) 30
R: TCTGCGCAAGTTAGGTTTTGTC 1237–1258
aEGFRvIII does not possess an mRNA-sequence distinct from the EGFR-1 sequence, but Exons 2–7 are missing. Using the indicated primers, EGFRvIII is characterised by a
product of 226bp size, while the wild-type receptor is recognised with a bp product of 1028bp. All templates were initially denaturated for 5min at 951C and the amplification
was extended at a final extension temperature of 721C for 7min.
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using TINA software (Raytest Isotopenmessgera ¨te, Straubenhardt,
Germany). For determination of up- and downregulation, the
mean optical density/mm
2 (OD/mm
2) of each gene was identified
and normalised to housekeeping gene expression (ubiquitin,
GAPDH, tubulin a 1 subunit, HLAC, cytoplasmic b-actin, 60S
ribosomal protein L13A, 40S ribosomal protein S9). Then the ratio
of gene expression in treated vs untreated cells was calculated. The
cutoff for upregulation was set at a 1.5-fold increase of the OD/
mm
2 ratio of genes in the treated samples, whereas downregulation
was determined as the 0.67-fold OD/mm
2 (reciprocal value of 1.5-
fold increase) expression of genes in the treated samples.
Western blotting
Whole-cell extracts were prepared by harvesting and lysing cells
with lysis buffer (sodium dodecyl sulphate (SDS) 0.1%, sodium
deoxycholic acid 0.5%, Nonidet P-40 1%, phenylmethylsulphonyl
fluoride (PMSF) 0.1mM, aprotinin 1mgml
 1, pepstatin A
1mgml
 1). The protein content of the lysate was determined using
the BCA protein assay kit (Pierce, Rockford, IL, USA). The cell
lysate was mixed with gel-loading buffer (Tris-HCl 62.5mM,
glycerol 10%, SDS 1%, b-mercaptoethanol 2.5%). After boiling
for 5min, the lysates were subjected to SDS/polyacrylamide gel
electrophoresis (30mg of protein per lane; gel: polyacrylamide 10%,
SDS 0.1%, Tris-HCl 25mM; running buffer: Tris 25mM, glycine
50mM, 0.1% SDS). After electrophoresis, gels were equilibrated
with transfer buffer (Tris-HCl 25mM, glycine 50mM, 20%
methanol). Proteins were transferred onto nitrocellulose mem-
branes by electroblotting (BioRad, Munich, Germany). Blots were
blocked in 1.5% bovine serum albumine (BSA), and then
incubated at 41C overnight with the total p38 mitogen-activated
protein kinase (MAPK) and phospho-p38 MAPK or the total
extracellular signal-regulated kinase 1/2 (ERK1/2) and phospho-
ERK1/2 antibodies, respectively (1:500, Santa Cruz Biotechnology,
CA, USA). After washing with phosphate-buffered NaCl solution
(PBS) containing 0.1% Tween and incubation with horseradish
peroxidase-coupled secondary antibody (1:10000, Amersham,
Uppsala, Sweden) at room temperature for 1h, the blot was
washed extensively and developed using enhanced chemilumines-
cent detection (Amersham, Uppsala, Sweden). Blots were exposed
to Hyperfilm ECL film (Amersham, Uppsala, Sweden) for 1–5min.
Immunofluorescence labelling
Cells were trypsinised, washed twice with PBS and immunostained,
as described previously (Sutter et al, 2002). Then samples were
fixed and permeabilised using the Fix & Perm cell permeabilisation
kit (Caltag, Laboratories, Hamburg, Germany). Cells were in-
cubated for 1h at room temperature with the primary rabbit
polyclonal IGF-b1 receptor antibody (5mgml
 1, # sc-713, Santa
Cruz) or with rabbit polyclonal EGF receptor antibody (5mgml
 1,
# sc-03, Santa Cruz), both mapping at the respective C-terminus of
the protein. Negative controls were performed by omitting the
primary antibody. Cells were washed twice with PBS and then
incubated with secondary FITC-labelled polyclonal anti-rabbit Ig
antibody (5mgml
 1, BD Pharmingen, Heidelberg, Germany) for
1h at room temperature. Fluorescence was detected by flow
cytometry on a FACSCalibur (Becton Dickinson, Heidelberg,
Germany) and analysed using CellQuest software.
Measurement of growth inhibition
Changes in the cell number of BON, CM and STC-1 cells were
determined by crystal violet staining after 96h of incubation with
rising concentrations of gefitinib (0–50mM). Measurements were
performed as described (Ho ¨pfner et al, 2001). Cells were washed
with PBS and fixed with 1% glutaraldehyde. After another washing
step, cells were stained with 0.1% crystal violet. The unbound dye
was removed by washing. Crystal violet that had absorbed onto the
cells was solubilised with 0.2% Triton X-100. Then light extinction
was analysed at 570nm using an ELISA reader.
Caspase-3 activity assay
Preparation of cell lysates and determination of caspase-3 activity
was performed as described previously (Maaser et al, 2002). The
activity of caspase-3 was calculated from the cleavage of the
fluorogenic substrate DEVD-AMC (Calbiochem-Novabiochem,
Bad Soden, Germany). Cell lysates were incubated with substrate
solution (caspase-3 substrate AC-DEVD-AMC 20mgml
 1, HEPES
20mM, glycerol 10%, DTT 2mM, pH 7.5) for 1h at 371C, and the
cleavage of DEVD-AMC was measured fluorometrically with a
VersaFluor fluorometer (excitation: 360nm emission: 460nm)
from Biorad, Munich, Germany.
DNA fragmentation
DNA fragmentation was determined by performing Cell Death
Detection ELISA (Roche) as described previously (Ho ¨pfner et al,
2003). Briefly, after 48h of incubation, cells were lysed with
incubation buffer. The cytoplasmic fractions were diluted to
contain 2.5 10
3 cell equivalents per ml, and the presence of
mono- and oligonucleosomes was assayed using antibodies
directed against DNA and histones. DNA fragments were detected
by a peroxidase system with colour development read at 405nm.
Cell-cycle analysis
Cell-cycle analysis was performed by the method of Vindelov and
Christensen, as described previously (Maaser et al, 2001). Cells
were trypsinised, washed and the nuclei were isolated using the
CycleTest PLUS DNA Reagent Kit (Becton Dickinson, Heidelberg,
Germany). DNA was stained with propidium iodide according to
the manufacturers’ instructions. The DNA content of the nuclei
was detected by flow cytometry and analysed using CellFit software
(Becton Dickinson).
Statistical analysis
The antineoplastic effects of the various substances and vehicles
were compared by the unpaired, two-tailed Mann–Whitney U-test.
The unpaired Student’s t-test was used for cell-cycle analysis. P-
values were considered to be significant at o0.05. If not stated
otherwise, all functional experiments were performed in quad-
ruplicate.
RESULTS
Expression of EGFR and IGFR in NE gastrointestinal
tumour cells
The mRNA expression of EGF receptors (EGFR) and the insulin-
like growth factor receptor b-1 (IGFR-b1) was investigated in
human BON and in human CM cells. The mRNAs specific for
EGFR and IGFRb-1 were detected in both the cell lines (Figure 1A,
B). To evaluate protein expression of both EGFR and IGFRb-1,
cells were stained with specific antibodies and analysed by flow
cytometry. Protein expression of EGFR and IGFR-b1 was detected
in both the cell lines (Figure 1C, D). By contrast, no expression of
the EGFR mutation, EGFRvIII, often observed in non-NE cancer
types, was detected in the human NE tumour models used (Figure
1A, B). Labelling murine STC-1 cells with specific antibodies for
EGFR and IGFR-b1 also confirmed the expression of both growth
factor receptors in this model of NE gut tumour cells (Figure 1D).
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Changes in the cell number caused by EGFR-TK inhibition were
studied by performing crystal violet assays. Gefitinib (0–50mM)
time- and dose-dependently inhibited the growth of all cell lines
investigated (Figure 2A–C). After 96h of incubation, a decrease of
almost 100% was observed. However, the IC50 values of gefitinib,
determined after 48h, differed between the three cell lines. While
in fast-growing CM cells (doubling time: 2171h) the IC50 value of
gefitinib amounted to 4.770.6mM, it was 16.870.4mM in the
moderate-growing BON cells (doubling time: 3474h), but as high
as 31.572.5mM in the slow-growing STC-1 cells (doubling time:
5476h) (Figure 2D).
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Figure 1 mRNA and protein expression of EGFR and IGFR in
neuroendocrine tumour cells. (A, B) mRNA expression of EGFRvIII (lane
1), EGFR-1 (lane 2) and IGFRb-1 (lane 3) was evaluated in CM (A) and
BON tumour cells (B). b-Actin was used as positive control (lane 4 in A
and B), 100bp DNA ladder. (C–E) Flow cytometric analysis of the
expression of EGFR and IGFRb-1 proteins in CM cells (C), BON cells (D)
and STC-1 cells (E). Black lines: cells stained with specific polyclonal
antibodies against either EGFR or IGFRb-1; grey lines: negative controls.
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Figure 2 Gefitinib-induced growth inhibition. Gefitinib caused a time-
and dose-dependent growth inhibition as measured by crystal violet
staining. The IC50 value was 4.770.6mM in fast-growing CM cells (A),
16.870.4mM in moderate-growing BON cells (B), and 31.572.5mM in
slow-growing STC-1 cells (C). (D) Correlation between the doubling time
of NE gastrointestinal tumour cells and their sensitivity to gefitinib
treatment. Data are given as the percentage of untreated controls
(means7s.e.m. of four to five independent experiments). * Statistical
significance (Po0.05).
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inhibited the growth of norepinephrine transporter (NET)-positive
NE gastrointestinal tumour cells with an IC50 value of 7.8mM
(Ho ¨pfner et al, 2002). Thus, it was intriguing to evaluate the
possible synergistic antiproliferative effects of the combination of
gefitinib with MIBG. Incubating NET-positive STC-1 cells for 3
days with combinations of sub-IC50 concentrations of MIBG
(5mM) and gefitinib (10mM) resulted in an overadditive
growth-inhibitory effect. While each drug alone decreased the
growth of STC-1 cells by either 23% (10mM gefitinib) or 28%
(5mM MIBG), the combination of both drugs led to a synergistic
antiproliferative effect of more than 90% growth inhibition (data
not shown).
Gefitinib and cell-cycle regulation
To test whether cell-cycle-arresting effects contributed to the
antiproliferative potency of gefitinib in NE gastrointestinal tumour
cells, we performed flow cytometric cell-cycle analysis. Challenging
CM and BON cells with rising concentrations of gefitinib (0–10mM
in CM, and 0–50mM in BON cells) for 48h dose-dependently
arrested CM and BON cells in the G1/G0 phase of the cell cycle,
thereby decreasing the proportion of cells in the S phase and G2/M
phase (Figure 3A, B). Interestingly, gefitinib did not affect the cell
cycle of STC-1 cells, even at the highest concentration of 50mM
(Figure 3C).
Proapoptotic effects of gefitinib
To check whether the induction of programmed cell death
contributed to the antineoplastic effects of gefitinib, we investi-
gated gefitinib-induced caspase-3 activation and DNA fragmenta-
tion in CM, BON and STC-1 cells.
Caspase-3 is a key enzyme in the apoptotic signalling pathway.
In all the three cell lines, gefitinib induced a dose-dependent
increase in caspase-3 activity (Figure 4). The extent of caspase-3
activation differed between the three cell lines. Interestingly,
caspase-3 activation was most pronounced in the slow-growing
STC-1 cells (7467122% increase), which on the other hand had
not displayed cell-cycle alterations in response to gefitinib
treatment. This suggests that the antiproliferative effect of gefitinib
in STC-1 cells is mainly caused by an induction of apoptosis. On
the other hand, fast-growing CM cells, which exhibited the most
pronounced G0/G1-arrest upon gefitinib treatment, showed the
lowest, albeit still distinctive, caspase-3 activation of the three NE
cell lines studied.
The fragmentation of DNA into mono- and oligonucleosomes is
a hallmark of apoptosis. Gefitinib dose-dependently induced DNA
fragmentation in NE gastrointestinal tumour cells (Figure 5). After
48h of incubation, an increase in DNA fragmentation of up to
approx. 380% of the control values was observed. The results on
DNA fragmentation confirm the notion that gefitinib potently
induces apoptosis in NE gastrointestinal tumour cells. The extent
of DNA fragmentation corresponded to the findings of caspase-3
activation in the respective cell line. Thus, strongest DNA
fragmentation was seen in STC-1 cells, while CM cells showed
less pronounced DNA fragmentation after incubation with
gefitinib.
Since the antiproliferative effect of MIBG on NET-positive STC-1
cells was mainly caused by an induction of apoptosis (Ho ¨pfner
et al, 2002), we wondered whether the overadditive antiprolifera-
tive effect of MIBG plus gefitinib was due to a synergistic induction
of apoptosis. After 48h of incubation, DNA fragmentation induced
by either drug amounted to 116% (10mM gefitinib) or 105% (1mM
MIBG), respectively. Combined incubation of STC-1 cells with
MIBG (1mM) and gefitinib (10mM) revealed an overadditive
activation of DNA-fragmentation of 141%.
Gefitinib-induced differential gene expression
The present work demonstrates that gefitinib induces both
apoptosis and cell-cycle arrest in NE gastrointestinal tumour cells.
To study the involved cell-cycle and apoptosis genes at the
transcriptional level, we performed cDNA microarray analysis of
gefitinib-treated CM cells. For microarray experiments, we chose a
concentration of 10mM gefitinib and a 48h incubation time, which
was shown to induce apoptosis and cell-cycle arrest in CM cells
maximally.
We found 35 genes to be differentially expressed in CM cells
upon gefitinib treatment. An asymmetric distribution of up- vs
downregulated genes became apparent (see Table 2). Among the
genes known to be involved in the apoptosis signalling cascade, the
expressions of caspase 4, PDCD 2, BCL-2-antagonist of cell death
(BAD) and the bcl-2 family protein harakiri were overexpressed in
gefitinib-treated cells. GADD 153, which plays an important role
both in apoptosis and G0/G1 arrest, was also upregulated. Among
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Figure 3 Induction of cell-cycle arrest by gefitinib. After 48h of
incubation with gefitinib, CM cells (A) and BON cells (B) dose-
dependently accumulated in the G0/G1-phase of the cell cycle. Accord-
ingly, the proportion of cells in the S and G2/M phases decreased in either
cell line. In contrast, no significant changes of cell-cycle phases were
observed in STC-1 cells (C). Means7s.e.m. of four independent
experiments for each cell line are shown. The difference of the proportion
of cells in a particular phase of the cell cycle vs control was significant for
7.5–10mM gefitinib in CM cells and for 10–50mM gefitinib in BON cells. *
Statistical significance (Po0.05).
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sthe genes being downregulated, the cell-cycle regulating kinases
ERK1, CDC-like kinase 3, cyclin-dependent kinase 10 and the DNA-
replication factor proliferating cell nuclear antigen (PCNA) were
found.
Gefitinib-mediated phosphorylation of ERK1/2 and p38
MAPK
To shed light on the signalling pathways influenced by EGFR-TK
inhibition, we investigated time-dependent alterations of the
phosphorylation of ERK1/2 and p38 MAPK, which are members
of the MAPK family known to be involved in EGFR signalling in
non-NE tumours. Incubating CM cells for 0–48h with 10mM
gefitinib revealed a time-dependent decrease in the phosphoryla-
tion of mitogenic ERK1/2 (Figure 6A). In contrast, no significant
alteration in the phosphorylation of the stress-activated p38 MAPK
was observed (Figure 6B).
DISCUSSION
EGFR signalling impacts on many aspects of tumour biology. The
activation of EGFR has been shown to enhance tumour growth,
invasion and spreading, and to inhibit apoptosis (Moghal and
Sternberg, 1999; Wells, 2000). In addition, the expression of EGFR
in tumours has been correlated with disease progression, poor
survival, poor response to therapy (Brabender et al, 2000) and the
development of resistance to cytotoxic agents (Wosikowski et al,
1997; Meyers et al, 1998). Thus, specific inhibition of EGFR and its
intrinsic TK activity by different strategies (e.g. monoclonal
antibodies, TK-inhibitors) has become a rationale for innovative
cancer treatment (Ciardiello et al, 2000; Cullinane et al, 2000;
Sirotnak et al, 2000; Overholser et al, 2000; Chan et al, 2001; Di
Lorenzo et al, 2002; Sewell et al, 2002; Mendelsohn, 2003), –
especially since the EGF receptor system is not only involved in
tumour growth but also plays a significant role in tumour invasion,
angiogenesis and adhesion (Woodburn, 1999; Ritter and Arteaga,
2003).
In the present study, we provide evidence that NE gastro-
intestinal tumour cells express both EGFR and the EGFR
transactivating IGFR-b1 (Gilmore et al, 2002). Moreover, gefitinib,
a specific EGFR-TK inhibitor, was found to inhibit potently the
growth of NE gastrointestinal tumour cells by inducing cell-cycle
arrest and/or apoptosis. The inhibition of EGFR-TK by gefitinib
led to a time- and dose-dependent growth inhibition by almost
100%. The effects were observed under foetal calf- and/or horse
serum-containing conditions, that is, in the presence of growth
factors like EGF, IGF and TGF-a. Under these in vivo-like serum
conditions, gefitinib was very potent, and thus qualifies as a
promising novel drug to be tested clinically in metastatic NE
gastrointestinal tumour disease.
The growth pattern of NE gastrointestinal tumours exhibits an
astonishingly wide spectrum ranging from very slow- to moderate-
growing types and finally to fast-growing, very aggressive types of
tumours (O ¨berg, 1994). In view of this particular background, it
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Figure 4 Gefitinib-induced caspase-3 activation. (A) In fast-growing CM
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slow-growing STC-1 cells showed increases in caspase-3 activation when
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experiments for each cell line). * Statistical significance (Po0.05).
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Figure 5 Gefitinib-induced DNA fragmentation. (A) Incubation of CM
cells with 1–10mM gefitinib for 48h led to a dose-dependent formation of
apoptosis-specific oligonucleosomes. (B) Dose-dependent increases in
DNA fragmentation of BON and STC-1 cells after 48h incubation with
gefitinib (1–50mM). Data are given as the percentage of untreated control
(means7s.e.m. of four independent experiments for each cell line). *
Statistical significance (Po0.05).
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swas important to check whether gefitinib was similarly capable of
inhibiting the proliferation of NE tumours with different growth
characteristics and to study the involved signalling pathways.
Therefore, we chose three models of NE gastrointestinal tumour
disease, each characterised by a different growth pattern and
different origin: first, human insulinoma CM cells, which have a
doubling time of 21h and represent ‘fast-growing’ NE tumour
cells. Second, human pancreatic carcinoid BON cells with a
doubling time of 34h, which represent ‘moderate-growing’ NE
tumour cells. Third, ‘slow-growing’ NE tumour cells of the gut
(STC-1 cells) with a doubling time of 54h. Each cell line was
cultured under its optimal growth conditions, which resulted in
different serum concentrations among the three cell lines. Never-
theless, the different serum concentrations were not responsible
for the different antineoplastic efficacies of gefitinib observed in
the three cell lines (data not shown). Although gefitinib effectively
inhibited tumour growth in each model, differences concerning
dose–response relationships and involved signalling pathways
became apparent. In fast-growing CM cells that displayed the
highest sensitivity to gefitinib (IC50 of 4.770.6mM), the anti-
neoplastic effect was based on both a moderate induction of
apoptosis and a strong G1/G0 phase arrest of the cell-cycle. In
moderate-growing BON cells also an induction of apoptosis as well
as an arrest in the G1/G0 phase of the cell-cycle were observed.
However, the concentrations needed to induce the antineoplastic
effects were significantly higher (IC50 of 6.870.4mM), and the
apoptotic response was more pronounced than in CM cells. On the
other hand, in slow-growing STC-1 cells displaying the lowest
Table 2 Transcripts differentially regulated in CM cells in response to gefitinib
GenBank ID Gene name Function Ratio
U28014 caspase 4 Caspase 4.13
M63167 rac protein kinase alpha Death kinase 3.27
S78085 Programmed cell death 2 Apoptosis-associated protein 3.13
U66879 BCL2-antagonist of cell death (BAD) bcl-2 family protein 2.81
Y00285 Insulin-like growth factor 2 receptor Growth factor receptor 2.55
U91985 DNA fragmentation factor alpha DNA fragmentation protein 2.52
M35410 Insulin-like growth-factor binding protein 2 Growth factor-binding protein 2.41
AF022385 Programmed cell death 10 Apoptosis-associated protein 2.40
X59798 Cyclin D1 Cyclin 2.27
M81934 Cell division cycle 25B Cell cycle protein 2.22
M32315 Tumour necrosis factor receptor superfamily, member 1B Death receptor 2.03
U66469 Cell growth regulatory with ring finger domain Cell cycle protein 1.99
U76376 harakiri, BCL2-interacting protein bcl-2 family protein 1.83
M25753 Cyclin B1 Cyclin 1.81
X66363 PCTAIRE protein kinase 1 cdc2-related protein kinase 1.76
U25265 Mitogen-activated protein kinase kinase 5 Intracellular kinase network member 1.76
S40706 GADD153 Apoptosis-associated protein 1.72
U78798 TNF receptor-associated factor 6 Death receptor-associated protein 1.72
X85134 Retinoblastoma-binding protein 5 Cell cycle protein 1.71
L25080 ras homologue gene family, member A Oncogene 1.70
M13228 v-myc myelocytomatosis viral-related oncogene Oncogene 1.68
M33294 Tumour necrosis factor receptor superfamily, member 1A Death receptor 1.67
M15796 Proliferating cell nuclear antigen DNA replication 0.65
D21090 RAD23 homologue B DNA damage signalling protein 0.65
S72008 Cell division cycle 10 Cell cycle protein 0.63
U39657 Mitogen-activated protein kinase kinase 6 Intracellular kinase network member 0.63
X66362 PCTAIRE protein kinase 3 cdc2-related protein kinase 0.61
U11791 Cyclin H Cyclin 0.58
X60188 Extracellular signal-regulated kinase 1 (ERK1) Cell cycle-regulating kinase 0.55
L05624 Mitogen-activated protein kinase kinase 1 Intracellular kinase network member 0.55
U75285 Survivin Apoptosis-associated protein 0.54
X79389 Glutathione S-transferase theta 1 Xenobiotic transporter 0.54
U78876 Mitogen-activated protein kinase kinase kinase 3 Intracellular kinase network member 0.50
U21092 TNF receptor-associated factor 3 Death receptor-associated protein 0.47
L07414 Tumour necrosis factor superfamily, member 5 Death receptor ligand 0.42
M73812 Cyclin E1 Cyclin 0.26
0         12       24  48
Gefitinib (10 M)
Gefitinib (10 M)
Time (h)
Time (h)
p-ERK1/2
ERK1/2
0     1         4  8  24 
p-p38
p38
Figure 6 Effect of gefitinib on MAP kinase activity in CM cells. CM cells
were treated with 10mM gefitinib for 0–48h. At the indicated time points,
the amount of phosphorylation of ERK1/2 and p38MAP kinases was
analysed by Western blotting. (A) Gefitinib induced a time-dependent
decrease in phosphorylated ERK1/2. (B) By contrast, no change in p38
MAPK phosphorylation was observed upon treatment with gefitinib.
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ssensitivity to gefitinib (IC50 31.572.5mM), the antineoplastic effect
was based on a strong induction of apoptosis, while no significant
cell-cycle alterations were observed.
The shift from a more cell-cycle arrest related action in fast-
growing NE tumour cells to an (almost) exclusively apoptosis-
related effect in slow-growing NE tumour cells may be important
to be taken into account when considering novel combination
therapies. In this respect, we were interested in the antiprolifera-
tive synergism between gefitinib and the norepinephrine derivative
MIBG. Nonradiolabelled MIBG has recently been suggested as an
innovative drug for the treatment of NE gastrointestinal tumours
expressing plasma membraneous norepinephrine transporters
(NET) (Taal et al, 1996; Ho ¨pfner et al, 2002). Since the
coapplication of MIBG and gefitinib resulted in an overadditive,
synergistic antiproliferative action in STC-1 cells, it is intriguing to
speculate whether in NET-positive NE tumours, the combination
of MIBG and gefitinib might be superior to either drug alone. The
mechanisms underlying the observed synergism, however, need
further investigation.
To further characterise the antiproliferative action of gefitinib
in NE gastrointestinal tumour cells, we studied the cell-cycle phase,
at which gefitinib might act. Upon gefitinib treatment, the
proportion of cells in the G1/G0 phase significantly increased
both in CM and BON cells. This suggests that gefitinib acts
at the G1/S checkpoint. Cell-cycle arrest by gefitinib at the
G1/S checkpoint had previously been described for other
tumours, such as head and neck cancer (Huang et al, 2002),
malignant pleural mesothelioma (Ja ¨nne et al, 2002) and breast
cancer (Janmaat et al, 2002). The latter tumour types mainly
represent fast-growing cancers known to be very sensitive to
growth factors. Many of these cancers produce and release
growth factors and thereby autostimulate themselves. This has
also been suggested for NE gastrointestinal tumours in which self-
produced transforming growth factor a (TGF-a) and insulin-like
growth factor (IGF) may autostimulate or transactivate EGFR and
thereby promote tumour cell growth (Nilsson et al, 1993, 1995). As
stromal components of midgut carcinoids also express EGFR,
growth factors like TGF-a may similarly contribute to the
desmoplastic reaction typical of midgut carcinoids (O ¨berg, 1994).
Thus, EGFR-TK inhibition might as well be a worthwhile strategy
to pursue for the control of the desmoplastic reaction and fibrosis
of carcinoid disease.
Induction of apoptosis by gefitinib has been reported previously
(Ciardiello et al, 2000; Huang et al, 2002; Janmaat et al, 2002).
However, the underlying mechanisms are not yet well understood
(Mendelsohn, 2002). In this paper, we report on the activation of
the proapoptotic enzyme caspase-3, which preceded the fragmen-
tation of nuclear DNA into oligonucleosomes. This indicates that
in NE tumour cells, gefitinib-mediated apoptosis is caspase-3
dependent. To support our functional data, we additionally
performed cancer-specific cDNA arrays, spotted with genes related
to proliferation, apoptosis and cell cycle. Treatment with gefitinib
resulted in an upregulation of proapoptotic and a suppression of
antiapoptotic genes of NE gastrointestinal tumour cells (Table 2).
The changes in the expression pattern of the several apoptosis-
related genes were consistent with both our functional data, and
reports showing that suppression of antiapoptotic and over-
expression of proapoptotic proteins caused programmed cell death
(Zamzami et al, 1996). Besides an overexpression of the cell cycle
and apoptosis relevant GADD153 gene (see below), a strong
upregulation of caspase 4, which has been implicated to play an
important role in the execution of apoptosis (Kamada et al, 1997),
was observed. We also observed a strong induction of proapopto-
tic BAD at the transcriptional level, suggesting a potential
involvement of this protein in gefitinib-induced apoptosis. As
suggested by others, a dephosphorylation of Akt/PKB by gefitinib
may be responsible for the activation of proapoptotic BAD
(Albanell et al, 2001). However, further investigations will have
to clarify the exact role of BAD in gefitinib-induced apoptosis of
NE tumour cells.
Gefitinib’s mode of action is known to include the suppression
of EGFR-TK-induced activation of MAP kinases, such as ERK1/2
(Albanell et al, 2001; Mendelsohn, 2002). Confirming this notion,
gefitinib did cause a time-dependent dephosphorylation and
transcriptional downregulation of ERK1/2 in NE tumour cells. In
addition, we observed an upregulation of the growth arrest and
DNA-damage inducible gene, GADD153, which is involved in G1/
G0 arrest (Wang and Ron, 1996; Oh-Hashi et al, 2001). The
expression of GADD153 is known to be regulated by both ERK1/2
and p38 MAPK: While p38 MAPK stimulates the expression of
GADD153, ERK1/2 inhibits the expression (Kultz et al, 1998; Oh-
Hashi et al, 2001). Interestingly, we did not observe any significant
effect of gefitinib on p38 MAPK activity in NE tumour cells. This
suggests that the upregulation of GADD153 by gefitinib is
mediated by a downregulation of ERK1/2, but not by increased
p38 MAPK activity.
Although gefitinib’s antiproliferative effect results from the
specific inhibition of EGFR-sensitive TK activity, gefitinib’s
antineoplastic potency not simply reflects the number of EGFRs
expressed. While some studies have reported a positive
correlation between EGFR expression and gefitinib’s antineo-
plastic action (Meye et al, 2001; Normanno et al, 2002), others
have found no such relationship (Ciardiello et al, 2000; Sirotnak
et al, 2000). One possible explanation for a missing correlation
between EGFR expression and gefitinib’s antiproliferative activity
may be the presence of constitutively active EGFR mutations, such
as EGFRvIII (Moscatello et al, 1995; Wikstrand et al, 1995;
Nishikawa et al, 1994). However, in neither NE gastrointestinal
tumour model used in this study, an expression of EGFRvIII
mutation could be detected and hence could not contribute to the
differing effects of gefitinib. Another reason for a missing positive
correlation could be EGFR transactivation by other growth factor
receptors (Arteaga, 2002). In this respect, Gilmore et al (2002)
recently demonstrated a transactivation of EGFR-TK by the
IGFR. Gefitinib suppressed the EGFR transactivation by IGFR,
and thereby induced apoptosis in breast cancer cells. EGFR
transactivation may also be important in NE gastrointestinal
tumours in which IGFR is commonly expressed and has
been implicated in growth control (Nilsson et al, 1993; Wulbrand
et al, 2000).
To conclude, our study provides evidence that the EGFR-TK
inhibitor gefitinib induces both cell-cycle arrest and apoptosis in
NE gastrointestinal tumour cells. Thus, gefitinib represents a
promising novel drug to be tested in patients with metastatic NE
gastrointestinal tumour disease.
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